Abiopharma

🔍 Chapman Rowan E (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2025-06-27

Detailed Transactions and Holdings:

• Acquired 2,143 shares of Common Stock (Direct)
  Date: 2025-06-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,345.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 271 shares of Common Stock (Direct)
  Date: 2025-06-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,616.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 149 shares of Common Stock (Direct)
  Date: 2025-07-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,765.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 2,750 shares of Common Stock at $166.99 per share (Direct)
  Date: 2025-08-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,015.00 | transaction_form_type: 4

Footnotes:

• F1: Represents the issuance of restricted stock units ("RSUs") that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: Represents the issuance of RSUs to the Reporting Person. 25% of the RSUs vest immediately and the remaining RSUs vest in three equal quarterly installments thereafter.
• F4: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $23,125 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.